Anidulafungin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IV Invasive candidiasis; Candidaemia; Candida infections (intra-abdominal abscess, peritonitis) Loading dose of 200 mg on day 1, then 100 mg once daily thereafter for at least 14 days after the last positive culture. Oesophageal candidiasis Loading dose of 100 mg on day 1, then 50 mg once daily thereafter for at least 14 days and for at least 7 days following resolution of symptoms. To be given by IV infusion. Max infusion rate: 1.1 mg/min.
Dosage Details
Intravenous
Oesophageal candidiasis
Adult: Loading dose of 100 mg on day 1, then 50 mg once daily thereafter. Continue treatment for at least 14 days and for at least 7 days following resolution of symptoms. To be given by IV infusion. Max infusion rate: 1.1 mg/min.
Elderly: No dosage adjustment needed.

Intravenous
Invasive candidiasis, Candidaemia, Candida infections (intra-abdominal abscess, pertonitis)
Adult: Loading dose of 200 mg on day 1, then 100 mg once daily thereafter. Continue treatment for at least 14 days after the last positive culture. To be given by IV infusion. Max infusion rate: 1.1 mg/min.
Elderly: No dosage adjustment needed.
Renal Impairment
No dosage adjustment needed.
Hepatic Impairment
No dosage adjustment needed.
Reconstitution
Reconstitute each 50 mg vial w/ sterile water for inj 15 mL, or each 100 mg vial w/ sterile water for inj 30 mL to provide a concentration of 3.33 mg/mL. Further dilute the reconstituted solution w/ either dextrose inj 5% or sodium chloride inj 0.9% to obtain a solution containing 0.77 mg/mL.
Incompatibility
Y-site administration: Sodium bicarbonate, ertapenem.
Contraindications
Hypersensitivity to anidulafungin or other echinocandins.
Special Precautions
Patients w/ serious underlying conditions receiving multiple concomitant medications w/ anidulafungin may experience hepatic abnormalities e.g. hepatitis, hepatic dysfunction or worsening hepatic failure. Pregnancy and lactation.
Adverse Reactions
Infusion-related reactions (e.g. pruritus, urticaria, rash, hypotension, dyspnoea, flushing); nausea, diarrhoea; phlebitis/thrombophlebitis, neutropaenia, hypokalaemia, headache; elevated alkaline phosphatase, hepatic enzymes, and γ-glutamyltransferase.
MonitoringParameters
Monitor liver function test.
Action
Description: Anidulafungin is a semi-synthetic echinocandin antifungal. It inhibits 1, 3-β-D-glucan synthesis, an essential component of the fungal cell walls. It has been shown to have in vitro activity against many Aspergillus spp and Candida spp.
Pharmacokinetics:
Distribution: Volume of distribution: 30-50 L. Plasma protein binding: >99%.
Metabolism: Undergoes slow chemical degradation to an open-ring peptide lacking antifungal activity. Not hepatically metabolised.
Excretion: Via faeces: <10% (as unchanged drug); urine: <1%. Terminal elimination half-life: 40-50 hr.
Storage
Reconstituted solution: Store up to 1 hr between 2-8°C prior to reconstitution. Infusion solution: Store between 2-8°C and should be administered w/in 24 hr. Do not freeze.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Anidulafungin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in